Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group

BACKGROUND: Combination chemotherapy is standard treatment for metastatic colorectal cancer (MCRC). The aim of this study was to determine the efficacy and safety of capecitabine+irinotecan (2-weekly schedule), as first-line therapy of MCRC. METHODS: Patients received irinotecan 175 mg m(−2) on day...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Alfonso, P, Muñoz-Martin, A, Mendez-Ureña, M, Quiben-Pereira, R, Gonzalez-Flores, E, Perez-Manga, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768107/
https://www.ncbi.nlm.nih.gov/pubmed/19738605
http://dx.doi.org/10.1038/sj.bjc.6605261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768107/
https://www.ncbi.nlm.nih.gov/pubmed/19738605
http://dx.doi.org/10.1038/sj.bjc.6605261

Ejemplares similares